Shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) have received a consensus recommendation of “Buy” from the seven brokerages that are presently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $10.65.
A number of analysts have recently weighed in on the stock. BidaskClub lowered shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. BMO Capital Markets reiterated a “buy” rating and issued a $12.00 price objective on shares of Tetraphase Pharmaceuticals in a research note on Friday, May 5th. HC Wainwright assumed coverage on shares of Tetraphase Pharmaceuticals in a research note on Tuesday, July 11th. They issued a “buy” rating and a $15.00 price objective on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Thursday, July 27th. Finally, Stifel Nicolaus upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and increased their price objective for the stock from $8.00 to $15.00 in a research note on Wednesday, July 26th.
In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 7,155 shares of the stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $5.86, for a total transaction of $41,928.30. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 5.50% of the company’s stock.
Institutional investors have recently bought and sold shares of the stock. EcoR1 Capital LLC bought a new position in Tetraphase Pharmaceuticals during the second quarter valued at about $4,516,000. State Street Corp increased its position in Tetraphase Pharmaceuticals by 6.4% in the second quarter. State Street Corp now owns 725,094 shares of the biopharmaceutical company’s stock valued at $5,165,000 after buying an additional 43,561 shares during the last quarter. PDT Partners LLC increased its position in Tetraphase Pharmaceuticals by 22.0% in the second quarter. PDT Partners LLC now owns 191,952 shares of the biopharmaceutical company’s stock valued at $1,369,000 after buying an additional 34,665 shares during the last quarter. Balyasny Asset Management LLC increased its position in Tetraphase Pharmaceuticals by 13.2% in the second quarter. Balyasny Asset Management LLC now owns 246,300 shares of the biopharmaceutical company’s stock valued at $1,756,000 after buying an additional 28,800 shares during the last quarter. Finally, Numeric Investors LLC increased its position in Tetraphase Pharmaceuticals by 1,363.3% in the second quarter. Numeric Investors LLC now owns 754,364 shares of the biopharmaceutical company’s stock valued at $5,379,000 after buying an additional 702,812 shares during the last quarter. 35.93% of the stock is currently owned by institutional investors and hedge funds.
WARNING: This story was published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://stocknewstimes.com/2017/08/24/tetraphase-pharmaceuticals-inc-ttph-receives-10-65-average-pt-from-brokerages.html.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded up 6.28% during trading on Monday, reaching $6.43. The company had a trading volume of 641,143 shares. The firm’s market capitalization is $328.27 million. Tetraphase Pharmaceuticals has a 12-month low of $3.11 and a 12-month high of $9.93. The firm’s 50 day moving average price is $6.60 and its 200 day moving average price is $7.08.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.76) by $0.07. The business had revenue of $1.59 million during the quarter, compared to analyst estimates of $1.54 million. Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. The firm’s revenue was up 28.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.47) EPS. Equities research analysts forecast that Tetraphase Pharmaceuticals will post ($2.55) EPS for the current year.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
